ATHE Bathi saben saham sajrone rolas wulan pungkasan Alterity Therapeutics Ltd.

The prospects for Alterity Therapeutics (ATHE) depend on the efficacy of therapies for neurodegenerative pathologies and patent protection. The TTM net income per share metric visualizes these expectations, where the value -0.90 reflects current dynamics. The business relies on third-party contractors (CRO/CMO) for drug development. High pre-revenue spending necessitates strict monitoring of the company's liquidity.
Rincian analitis lan laporan data perusahaan alteritytherapeutics.com (ATHE)

Assessing the financial strength of Alterity Therapeutics (ATHE) requires an analysis of the business's ability to generate real income. This indicator calculates the final profit allocated per ordinary share, excluding the impact of the total issuance volume. The net income per share trend over the last four quarters demonstrates the efficiency of capital management. For a company scaling the ATH434 drug, this metric reflects the balance between neuropharmacology expansion costs and financial stability.